labetalol has been researched along with Bradycardia in 13 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Bradycardia: Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 9.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| "To assess the safety and efficacy of continuous infusion (CIV)-labetalol compared to -nicardipine in controlling blood pressure (BP) in the acute stroke setting." | 8.02 | Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine? ( El-Ghoroury, H; Hecht, JP; Sudekum, DM, 2021) |
| "The episode of profound hypotension which occurred after initiating a labetolol infusion required maximal combined vasopressor therapy to restore the blood pressure suggesting that this patient demonstrated an extreme sensitivity to labetalol." | 7.73 | Case report: profound hypotension associated with labetalol therapy in a patient with cerebral aneurysms and subarachnoid hemorrhage. ( Baker, AJ; Choi, M; Hare, GM; Jivraj, S; Mazer, CD, 2006) |
| "It was discovered that labetalol withdrawal effects initially cause various degrees of hypotension, hypoglycemia, and bradycardia among exposed neonates." | 5.12 | Distinct outcomes of labetalol exposed infants: case reports and systematic review. ( Hui, L; Long, H; Yang, X; Zou, L, 2021) |
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 5.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| "To assess the safety and efficacy of continuous infusion (CIV)-labetalol compared to -nicardipine in controlling blood pressure (BP) in the acute stroke setting." | 4.02 | Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine? ( El-Ghoroury, H; Hecht, JP; Sudekum, DM, 2021) |
| " labetalol hydrochloride with doses greater than 300 mg in 24 hours observed a high rate of bradycardia and hypotension, but the study found that these events rarely caused clinically significant hemodynamic compromise and was not statistically associated with adverse events." | 3.91 | Safety of high-dose intravenous labetalol in hypertensive crisis. ( Brandt, MM; Hecht, JP; Mahmood, SM, 2019) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| "The episode of profound hypotension which occurred after initiating a labetolol infusion required maximal combined vasopressor therapy to restore the blood pressure suggesting that this patient demonstrated an extreme sensitivity to labetalol." | 3.73 | Case report: profound hypotension associated with labetalol therapy in a patient with cerebral aneurysms and subarachnoid hemorrhage. ( Baker, AJ; Choi, M; Hare, GM; Jivraj, S; Mazer, CD, 2006) |
| "A single 30 mg intravenous dose of labetalol given 20 minutes prior to cesarean delivery at 35 weeks of gestation for severe pregnancy-induced hypertension was associated with symptoms of beta-adrenergic blockade (hypoglycemia, bradycardia, hypotension) in preterm twins." | 3.69 | Neonatal adrenergic blockade following single dose maternal labetalol administration. ( Bhatt-Mehta, V; Donn, SM; Klarr, JM, 1994) |
| " Safety was assessed according to adverse events that occurred during labetalol administration." | 1.91 | Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients. ( Duangprasert, G; Durongkaweroj, P; Noiphithak, R; Sukhor, S; Yindeedej, V, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Noiphithak, R | 1 |
| Duangprasert, G | 1 |
| Sukhor, S | 1 |
| Durongkaweroj, P | 1 |
| Yindeedej, V | 1 |
| Yang, X | 1 |
| Hui, L | 1 |
| Long, H | 1 |
| Zou, L | 1 |
| El-Ghoroury, H | 1 |
| Sudekum, DM | 1 |
| Hecht, JP | 2 |
| Singla, D | 1 |
| Parashar, A | 1 |
| Pandey, V | 1 |
| Mangla, M | 1 |
| Mahmood, SM | 1 |
| Brandt, MM | 1 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Seely, EW | 1 |
| Mogun, H | 1 |
| Maeda, A | 1 |
| Fischer, MA | 1 |
| Hernandez-Diaz, S | 1 |
| Huybrechts, KF | 1 |
| Jivraj, S | 1 |
| Mazer, CD | 1 |
| Baker, AJ | 1 |
| Choi, M | 1 |
| Hare, GM | 1 |
| Klarr, JM | 1 |
| Bhatt-Mehta, V | 1 |
| Donn, SM | 1 |
| Dannon, PN | 1 |
| Iancu, I | 1 |
| Hirschmann, S | 1 |
| Ross, P | 1 |
| Dolberg, OT | 1 |
| Grunhaus, L | 1 |
| Huang, YC | 1 |
| Wu, BN | 1 |
| Lin, YT | 1 |
| Chen, SJ | 1 |
| Chiu, CC | 1 |
| Cheng, CJ | 1 |
| Chen, IJ | 1 |
| Pittman, JA | 1 |
| Kross, RA | 1 |
| Ferri, E | 1 |
| Leung, D | 1 |
| Pratila, M | 1 |
| Broad, C | 1 |
| Veronesi, M | 1 |
| Melendez, JA | 1 |
| Flamenbaum, W | 1 |
| Weber, MA | 1 |
| McMahon, FG | 1 |
| Materson, BJ | 1 |
| Carr, AA | 1 |
| Poland, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficiency of Intravenous Lidocaine to Reduce Coughing and the Hemodynamic Changes Associated to Tracheal Extubation[NCT03731429] | Phase 4 | 144 participants (Anticipated) | Interventional | 2019-04-05 | Recruiting | ||
| Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy[NCT01951950] | Phase 1 | 40 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01951950)
Timeframe: 1 hour postoperatively
| Intervention | participants (Number) |
|---|---|
| Nicardipine | 1 |
| Esmolol | 11 |
1 review available for labetalol and Bradycardia
| Article | Year |
|---|---|
Distinct outcomes of labetalol exposed infants: case reports and systematic review.
Topics: Bradycardia; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Labetalol; Maternal Exposur | 2021 |
4 trials available for labetalol and Bradycardia
| Article | Year |
|---|---|
Comparative evaluation of dexmedetomidine and labetalol for attenuating hemodynamic stress responses during laparoscopic cholecystectomy in borderline hypertensive patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Blood Pressure; Bradycardia; Cholecystectomy, Laparosco | 2019 |
Labetalol does not lengthen asystole during electroconvulsive therapy.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adult; Aged; Blood Pressure; Bradycardia; Combi | 1998 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
Monotherapy with labetalol compared with propranolol. Differential effects by race.
Topics: Adult; Aged; Black or African American; Bradycardia; Clinical Trials as Topic; Dizziness; Double-Bli | 1985 |
8 other studies available for labetalol and Bradycardia
| Article | Year |
|---|---|
Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients.
Topics: Blood Pressure; Bradycardia; Humans; Hypotension; Labetalol; Retrospective Studies | 2023 |
Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pre | 2021 |
Safety of high-dose intravenous labetalol in hypertensive crisis.
Topics: Administration, Intravenous; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bradycardia; Dose | 2019 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
Case report: profound hypotension associated with labetalol therapy in a patient with cerebral aneurysms and subarachnoid hemorrhage.
Topics: Antihypertensive Agents; Bradycardia; Cardiotonic Agents; Dopamine; Epinephrine; Female; Humans; Hyp | 2006 |
Neonatal adrenergic blockade following single dose maternal labetalol administration.
Topics: Adult; Bradycardia; Diseases in Twins; Female; Fetal Blood; Humans; Hypoglycemia; Hypotension; Infan | 1994 |
Eugenodilol: a third-generation beta-adrenoceptor blocker, derived from eugenol, with alpha-adrenoceptor blocking and beta2-adrenoceptor agonist-associated vasorelaxant activities.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Anesthesia; Animals; Aorta, Thoracic; Bradyca | 1999 |
Magnesium sulphate for pre-eclampsia and a sudden bradycardia.
Topics: Adolescent; Adrenergic beta-Antagonists; Bradycardia; Calcium Channel Blockers; Drug Interactions; F | 2000 |